Eng

Ivomec

Quick links to important sections

Ivomec

Ivermectin

Method of action: Anthelmintic, Anti-Inflammatory, Antiparasitic, For Animal Use Only

Treatment option: Infection

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ivomec

Property	Description
Active ingredient	Ivermectin
Form	Sterile non-aqueous solution (Injectable), Oral Drench/Paste
Pharmacological class	Endectocide / Macrocyclic Lactone
Common use	Broad-spectrum antiparasitic control in livestock
Origin	Semisynthetic compound (derived from Streptomyces avermitilis)

What is Ivomec and What Type of Drug is It?

Ivomec is an established veterinary antiparasitic agent renowned for its efficacy against numerous internal and external parasites in livestock. The medication's core therapeutic component is the active ingredient, Ivermectin, a substance recognized globally for its role in systemic parasite management. Ivermectin is chemically designated as a semisynthetic compound belonging to the macrocyclic lactone class, derived from the fermentation products of the soil bacterium Streptomyces avermitilis.

The specific classification as a macrocyclic lactone reflects the compound's ability to selectively disrupt nerve and muscle function unique to parasites. This feature allows for a targeted approach to parasite control. Ivomec is distinctively formulated primarily as a sterile non-aqueous solution for subcutaneous injection, setting it apart from oral-only formulations and allowing for predictable absorption necessary for its systemic action.

Ivermectin's Pharmacological Class: The Endectocide

Ivermectin is pharmacologically categorized as an endectocide, meaning it is clinically recognized for its broad-spectrum activity against both endoparasites (internal worms) and ectoparasites (external arthropods). This dual function provides comprehensive, single-product management of the overall parasite burden.

Ivermectin is a veterinary drug for treating parasitic infections in animals. As an endectocide, the medicine's general purpose is to facilitate systemic parasite elimination, effectively clearing organisms such as gastrointestinal worms and mange mites, thereby protecting the health and welfare of the animal population.

What side effects are possible with Ivomec?

Possible Side Effects and Safety Information

The official safety profile for the active ingredient, Ivermectin, defines potential adverse reactions through classifications based on frequency and affected physiological systems, as established by government regulatory documents (e.g., FDA and EMA).

Reactions are often grouped into System-Organ Classes, which include Nervous System Disorders (e.g., headache, dizziness, and rarely, seizure or confusion), Gastrointestinal Disorders (e.g., nausea, vomiting, diarrhea), and Skin and Subcutaneous Tissue Disorders (e.g., pruritus, rash, and urticaria).

Frequency-Classified Adverse Reactions

Regulatory labeling documents classify certain effects based on incidence:

Classification	Examples of Officially Documented Effects
Very Common	Eosinophilia (increased white blood cell count), Musculoskeletal pain, Pruritus, Headache.
Common	Dizziness, Peripheral swelling (edema), Diarrhea, Hyponatremia.

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights serious, though rare, adverse reactions. These include severe forms of neurotoxicity, such as stupor or coma, and potentially fatal encephalopathy, particularly documented in patients with a high burden of Loa loa infection. Serious skin reactions, such as Stevens-Johnson syndrome (SJS), are also listed as rare adverse events.

Specific time-related patterns are noted, such as Mazzotti reactions (inflammatory responses related to parasite death) generally occurring and resolving within the first week following treatment, and orthostatic hypotension being most common on Days 1 and 2. Safety constraints include contraindications for individuals with known hypersensitivity to any component of the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

The Ivermectin overdose profile, as documented in regulatory labeling, is characterized by specific Central Nervous System (CNS) and systemic manifestations. When overdose is suspected, official guidance mandates immediately seeking medical attention.

Documented Manifestations	Severe Outcomes
CNS effects: ataxia, tremors, lethargy, confusion, and hallucinations. Gastrointestinal effects: nausea, vomiting, abdominal pain, and diarrhea. Cardiovascular effects: hypotension and tachycardia are also reported.	Seizures, coma, respiratory failure, and death are documented outcomes associated with massive or severe overdose.

Required Emergency Actions and Supportive Management

Official regulatory texts require that individuals experiencing or suspected of an Ivermectin overdose must seek immediate medical attention. This action is necessary due to the potential for rapid escalation to life-threatening conditions, which requires prompt hospital monitoring and intervention.

No specific antidote is known to exist for Ivermectin toxicity. Management is therefore entirely focused on providing symptomatic and supportive therapy. Regulatory descriptions of this support include continuous observation and monitoring of vital signs, the use of parenteral fluids, and, if clinically indicated, gastric decontamination procedures such as gastric lavage and the administration of activated charcoal to prevent further absorption.

Therapeutic Uses of Ivomec

What Ivomec Treats: Main Uses and Benefits

Ivomec is a veterinary antiparasitic generally used to manage a wide array of parasitic conditions in livestock. Its core use supports the management of the parasitic burden, which may assist with animal health and productivity. Ivermectin 1% solution is indicated for use in cattle and swine for the treatment of internal and external parasites, and is generally used because of its broad-spectrum applicability.

This therapy is commonly used to help manage conditions marked by heightened physiological strain due to internal parasites, such as gastrointestinal roundworms and lungworms, and external infestations, including mange mites and lice. This use helps manage symptom clusters that create noticeable functional strain like suppressed appetite and inadequate weight gain, as well as symptoms related to inflammatory states like intense itching and hair loss.

“This therapeutic approach provides support that helps ease the overall symptom burden, contributing to supporting the animal's function and well-being.”

The medication is relevant when supportive symptom management is appropriate within larger, planned clinical scenarios, such as treating breeding animals (cows, sows) during phases of increased physiological stress. This use offers symptomatic relief that helps patients cope more steadily with difficult episodes and contributes to supporting comfort.

Quick Fact: Relief for Dermatological Distress

Ivomec supports the management of conditions where external parasites cause symptoms related to inflammatory or irritative states.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Ivermectin

Regulatory agencies define strict criteria for the use of ivermectin (Stromectol). The primary absolute contraindication is a known hypersensitivity to ivermectin or any inactive ingredients in the formulation.

Population Group	Eligibility Status (Regulatory Label)
Pediatric Patients	Safety and effectiveness have not been established in children weighing less than 15 kg (approximately 33 lbs).
Pregnant Women	Generally not recommended (FDA Pregnancy Category C). Use is restricted to cases where the benefit clearly outweighs the potential risk to the fetus.
Breastfeeding Women	Ivermectin is excreted in low concentrations in breast milk. Use is permitted only if the risk of delayed treatment to the mother outweighs the possible risk to the newborn.
Elderly Patients	Use is allowed, but caution is advised due to the higher likelihood of age-related hepatic (liver) or renal (kidney) impairment.

Additional restrictions apply to patients with specific clinical conditions. Individuals who have had significant exposure to Loa loa-endemic areas require pretreatment assessment due to the risk of rare, serious encephalopathy if the microfilarial load is high. Immunocompromised patients may require repeated courses of therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ivomec (Ivermectin) has documented interaction patterns that are primarily classified based on how co-administered substances alter its systemic concentrations or its effects on the central nervous system (CNS).

Official Interaction Statements

Category	Interacting Entities and Documented Regulatory Outcome
Exposure Modification	Drugs that inhibit CYP3A4-mediated metabolism (e.g., certain Antifungals) may slow the breakdown of Ivermectin and are documented to increase its plasma concentrations.
Pharmacodynamic Potentiation	CNS Depressants (including Alcohol) may cause additive effects, which can increase the risk of CNS-related side effects, such as sleepiness or confusion.
Coagulation Risk	Anticoagulants (e.g., Warfarin) may have their effects enhanced when co-administered, potentially increasing the risk of unwanted bleeding.
Specific Disease Risk	Diethylcarbamazine citrate (DEC-C) and similar microfilaricidal agents, when co-administered in patients heavily co-infected with Loa loa, carry a specific risk of severe neurological events.
Food / Timing Rule	Food is documented to increase the oral absorption of Ivermectin, which is a pharmacokinetic factor used to define administration timing constraints.

Interaction-Context Constraints

The regulatory profile highlights that the drug is mainly metabolized by the CYP3 A4 enzyme, forming the mechanistic basis for clinically significant exposure-altering interactions with potent CYP3 A4 inhibitors. Warnings also exist for the potential for enhanced pharmacodynamic effects when Ivermectin is used alongside other substances that affect the CNS. Furthermore, the official documents contain specific constraints related to the potential for severe adverse reactions in populations with certain parasitic co-infections.

Mechanism of Action

The mechanism of Ivermectin is defined by its selective interaction with the glutamate-gated chloride channels ( GluCl), which are specific to the nerve and muscle cells of target parasites. Ivermectin acts as a direct agonist, causing the GluCl channels to open and inducing a substantial, sustained influx of chloride ions ( Cl^-). This molecular event drives the parasite's nerve and muscle cell membranes into a state of hyperpolarization, effectively suppressing their ability to generate and transmit electrical signals.

This sustained cellular inhibition triggers a cascade leading to flaccid paralysis and immobility of the parasite's somatic muscles. The mechanism also affects internal musculature, such as the pharyngeal pump, leading to the cessation of feeding and reproductive function. Selectivity is maintained because mammalian hosts lack GluCl channels, and the P-glycoprotein ( P-gp) efflux pump at the blood-brain barrier actively modulates the drug's distribution in the host's central nervous system.

Dosage and Administration Information

How Ivomec is Used: Official Administration Principles

The administration of Ivomec (Ivermectin) follows established protocols for its use in livestock. The injectable formulation, typically provided as a 1% sterile solution, is for subcutaneous injection (SC) only. Other forms may be available for topical application as a pour-on solution, providing alternative administration options.

The regimen is governed by a weight-based dosing rule. For cattle, the specified dose is 200mu g/kg of body weight, while swine require 300mu g/kg. This calculation ensures the volume administered, such as 1 mL per 50 kg (110 lb) for cattle, adheres to established standards.

The frequency of use generally follows a single-dose protocol for individual treatment. However, specific populations, notably breeding animals, involve strategic intermittent administration, such as treatment scheduled 7–14 days prior to farrowing for sows. Procedural instructions govern the physical application, including using sterile equipment and adhering to precise anatomical sites, such as the neck for swine. Furthermore, a constraint requires that no more than 10 mL of the solution be injected at any single site in cattle; larger calculated doses must be divided across multiple locations. These standardized instructions collectively define the protocol for the medicine's application.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Ivomec

Research exploring Ivomec's role against internal parasites focuses on Controlled Studies and regulatory reviews. These studies examine large animal populations, including cattle, swine, and sheep, focusing on conditions characterized by internal parasitic infections. Research monitored changes during the study period by measuring the Fecal Egg Count Reduction (FECR), which tracks the number of parasite eggs before and after the study medicine was administered. Findings described patterns related to parasite load reduction and explored secondary outcomes such as Body Weight Gain and evaluating patterns related to physical discomfort symptoms.

Research examining Ivomec's role against external parasites, such as mites and lice, was evaluated in controlled studies and field trials. Researchers monitored changes in the physical count of ectoparasites on the host animal and patterns related to the time course of clinical signs like itching and hair loss. Research has also explored the use of Ivomec as a broad-spectrum endectocide, mainly through Large-scale Field Trials, monitoring functional outcomes like Average Daily Weight Gain and Body Condition Scores in various populations.

The research follow-up duration is generally concentrated on the short- to intermediate-term, typically covering the period required for acute parasite load reduction over approximately 28 days. Long-term effects are not fully established. The major area of scientific uncertainty is the ongoing global documentation of parasite resistance to the macrocyclic lactone class of drugs. Research is ongoing to continuously track this evolving resistance, indicating that certainty remains low regarding sustained universal effectiveness across all regions.

Key Studies & References FREEDOM OF INFORMATION SUMMARY ORIGINAL NEW ANIMAL DRUG APPLICATION ANADA 200-228 PhoenectinTM Injection for Cattle and Swine (1% ivermectin) - FDA

How should Ivomec be stored and disposed of?

How to Store and Dispose of Ivomec?

The storage and disposal of Ivomec must strictly adhere to official regulatory conditions to ensure product stability and environmental safety.

Scope Element	Official Regulatory Statement
Storage Temperature	Store at controlled room temperature, typically 68-77 F (20-25 C), and generally below 86 F (30 C).
Environmental Protection	Must be protected from light and heat, and kept away from sparks or open flames.
Container & Handling	Store the container tightly closed and in its original carton. Keep the product out of the reach and sight of children.
Disposal Requirements	Disposal must follow local, regional, and national regulations. Due to its classification as Extremely Dangerous to Fish and Aquatic Life, the product must not be disposed of in wastewater or surface waters.

These instructions define mandatory constraints on the storage environment, emphasizing temperature control, light exclusion, and fire prevention. Final disposal procedures are governed by strict environmental hazard rules, requiring compliance with controlled waste protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.